Meghívásos bevonás
Comparing an AI-driven Hearing Test With the Standard Hearing Test in Adults With Hearing Loss and Tinnitus
NCT07895004· University College, London· Forrás
Toboroz
An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
NCT07665723· 1. fázis· Hoffmann-La Roche· Forrás
Toboroz
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152· 3. fázis· Immuneering Corporation· Forrás
Contact: Study Team
Toboroz
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma
NCT07300683· 1. fázis· University College, London· Forrás
Contact: FRACTALL Trial Manager
Toboroz
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06948318· 3. fázis· Takeda· Forrás
Contact: Marie Ann Scully (principal investigator)
Toboroz
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232· 1/2. fázis· BioNTech SE· Forrás
Fut, nem toboroz
A Study to Assess THN391 in Subjects With Alzheimer's Disease
NCT06814730· 1. fázis· Therini Bio, Inc.· Forrás
Toboroz
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568· 3. fázis· BioNTech SE· Forrás
Toboroz
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06722235· 3. fázis· Takeda· Forrás
Toboroz
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT06669247· 1/2. fázis· Regeneron Pharmaceuticals· Forrás
Contact: Clinical Trials Administrator
Toboroz
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
NCT06667908· 2. fázis· Johnson & Johnson Enterprise Innovation Inc.· Forrás
Toboroz
Diagnostic Concordance of MR Enterography and Ultrasound for Treatment Response Assessment in Crohn's Disease (MANTRA)
NCT06800326· University College, London· Forrás
Contact: Michelle Berin
Fut, nem toboroz
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441· 3. fázis· Gilead Sciences· Forrás
Toboroz
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
NCT06500884· 2. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
NCT06292780· 1/2. fázis· Regeneron Pharmaceuticals· Forrás
Contact: Clinical Trials Administrator
Toboroz
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
NCT06520345· 3. fázis· Telix Pharmaceuticals (Innovations) Pty Limited· Forrás
Contact: GU Research
Toboroz
SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
NCT05990192· 2. fázis· Institute of Cancer Research, United Kingdom· Forrás
Contact: Janani Vijeyakumar
Toboroz
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
NCT06385080· 1/2. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025· 2/3. fázis· Daiichi Sankyo· Forrás
Toboroz
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
NCT06064890· 1/2. fázis· AviadoBio Ltd· Forrás
Contact: GENFI Research Team
Toboroz
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
NCT05080556· 2. fázis· University College, London· Forrás
Contact: Michelle Lockley
Fut, nem toboroz
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT05840211· 3. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
NCT05608291· 3. fázis· Regeneron Pharmaceuticals· Forrás
Fut, nem toboroz
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
NCT05688280· 1/2. fázis· Immunophotonics, Inc.· Forrás
Toboroz
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
NCT05498428· 2. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1
NCT05481879· 1/2. fázis· Dyne Therapeutics· Forrás
Fut, nem toboroz
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286· 3. fázis· Gilead Sciences· Forrás
Toboroz
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
NCT04811560· 1/2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038· 3. fázis· Loxo Oncology, Inc.· Forrás
Fut, nem toboroz
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004· 2. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
NCT04534205· 2/3. fázis· BioNTech SE· Forrás
Toboroz
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT03564340· 1/2. fázis· Regeneron Pharmaceuticals· Forrás
Contact: Clinical Trials Administrator
Fut, nem toboroz
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT03431350· 2. fázis· Janssen Research & Development, LLC· Forrás